文献速递膀胱癌与上尿路尿路上皮癌

氟-18-脱氧葡萄糖PET/CT在浸润性膀胱癌组织学亚型分期中的诊断价值

Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-03-06

本研究纳入112例组织学亚型(HS)含量≥75%的浸润性膀胱癌患者,评估[18F]FDG-PET/CT对原发肿瘤的可视化及分期改变。结果显示87%原发肿瘤FDG高摄取,20%患者分期被修改(主要为升期),支持其作为HS分期的补充手段。

要点

  • HS以神经内分泌癌(40%)和鳞癌(34%)为主,原发肿瘤FDG高摄取率87%。
  • [18F]FDG-PET/CT使20%患者分期改变,主要为升期。
  • 纯性与混合性HS间FDG摄取及分期影响差异小。

核心结论

  • [18F]FDG-PET/CT对HS原发肿瘤可视化率高,且每5例中1例分期改变,支持作为HS分期的补充 modality。

研究设计与样本

  • 单中心回顾性纳入112例组织学确认的IBC(HS含量≥75%),2012-2024年于国家综合癌症中心治疗,均行CECT和[18F]FDG-PET/CT。
  • 主要终点为原发肿瘤可视化,次要终点包括增量诊断价值(与CECT相比淋巴结或转移分期改变)、与匹配UC队列的探索性比较及病理相关性评估。

主要发现

  • 主要HS为神经内分泌癌(40%)、鳞状细胞癌(34%)、腺癌(11%)和肉瘤样癌(11%)。
  • 原发肿瘤FDG高摄取占87%,FDG阴性占5%;20%患者[18F]FDG-PET/CT修改分期,主要为升期。
  • 各HS间及纯性(≥95%)与混合性(75-94%)含量间FDG摄取和分期影响差异小;匹配UC队列显示类似的PET/CT诱导分期改变率。

临床怎么用

  • 在HS含量≥75%的浸润性膀胱癌分期中,可考虑[18F]FDG-PET/CT作为补充手段,尤其关注其升期潜力。

局限性

  • 病理确认仅限于小部分选择性子组,限制诊断准确性的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Up to 25% of bladder cancer cases harbour histological subtypes (HSs) distinct from conventional urothelial carcinoma (UC), often with more aggressive behaviour and variable treatment response. Accurate staging is essential, but the optimal approach for HSs remains unclear. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) may improve staging in invasive bladder cancer (IBC), though its value in HSs is unestablished. This study evaluates the diagnostic performance and utility of [18F]FDG-PET/CT in staging HSs. METHODS: We included 112 patients with histologically confirmed IBC containing ≥75% HS content, treated at a national comprehensive cancer centre (2012-2024). An expert pathological review was performed. All patients underwent standard staging with contrast-enhanced CT (CECT) and [18F]FDG-PET/CT. The primary endpoint was visualisation of the primary tumour. The secondary endpoints included incremental diagnostic value (change in nodal or metastatic stage compared with CECT), exploratory comparison with a matched UC cohort, and pathological correlation assessment. KEY FINDINGS AND LIMITATIONS: The predominant HSs were neuroendocrine carcinoma (40%), squamous cell carcinoma (34%), adenocarcinoma (11%), and sarcomatoid carcinoma (11%). The primary tumour was FDG-avid in 87%, and FDG-negative in 5%. In 20%, [18F]FDG-PET/CT modified staging, mainly through upstaging. Differences in FDG avidity and staging impact across HSs and between pure (≥95%) and mixed (75-94%) content were small. A matched UC cohort showed similar rates of [18F]FDG-PET/CT-induced stage modification. Pathological confirmation was limited to a small selected subgroup, restricting the assessment of diagnostic accuracy. CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of [18F]FDG-PET/CT demonstrated high visualisation rates for primary tumour detection and altered staging in one of five patients, supporting its consideration as a complementary modality in HS staging.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lijnen RAG, Ringia JB, Claps F, et al. Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer. Eur Urol Oncol. 2026. PMID: 41794597. doi:10.1016/j.euo.2026.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。